Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing reevaluation of PEG-rhG-CSF versus rhG-CSF for prevention of chemotherapy-induced neutropenia in malignant lymphoma
ChiCTR1800017621Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegfilgrastim and filgrastim in lymphosarcoma (2 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Duration of grade 3 or 4 neutropenia during the first observation cycle. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
pegfilgrastimfilgrastim
03
Conditions
lymphosarcoma
Beyond the preview
Go deeper on ChiCTR1800017621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017621.